Unlock measurable value at every stage of the clinical development and commercialization journey.
Discover how Inizio helped Tonix launch the first FDA-approved therapy in its class in almost two decades.
Obesity management is rapidly evolving, and the definition of successful treatment is evolving with it. Drawing on recent discussions with clinicians across specialties, Tom Rotolo, Vice President, Medical Strategy at MEDiSTRAVA, explores how perspectives on successful obesity treatment are shifting beyond the magnitude of weight loss to consider how weight is lost, what tissue is lost, and whether improvements translate into better long-term health and function.
One emerging concern is the speed of weight reduction. While substantial weight loss can deliver important metabolic benefits, clinicians have highlighted the potential consequences of losing weight too rapidly, particularly among older, frail, or physically inactive patients. Loss of lean muscle mass may contribute to reduced strength, fatigue, impaired mobility, and diminished functional reserve, reinforcing the importance of balancing efficacy with preservation of muscle and physical function.
These perspectives reflect a broader shift from “maximizing weight loss” toward “optimizing health.” Body composition, visceral and organ fat, metabolic health, tolerability, quality of life, and functional outcomes are becoming increasingly relevant measures of treatment success.
Importantly, specialist priorities differ from primary care. From our recent discussions, primary care clinicians focus on practical implementation and day-to-day management; endocrinologists emphasize integrated metabolic health; gastroenterology and hepatology specialists prioritize liver-related outcomes; and obesity medicine specialists place greater emphasis on body composition, patient experience, and individualized care.
Real-World iNSIGHTS can help translate these diverse perspectives into actionable strategy. By combining structured discussion, polling, specialty-specific perspectives, and real-world data, these programs can reveal how clinicians interpret emerging evidence, where evidence gaps or implementation barriers remain, and which outcomes resonate most strongly in practice.
For medical teams, Real-World iNSIGHTS can inform evidence generation, scientific communication, education, and stakeholder engagement. For commercial teams, we can help identify audience-specific needs, regional differences, adoption barriers, and areas where emerging data may have the greatest relevance, providing a clearer bridge between clinical evidence and real-world decision-making.
Join us at ObesityWeek® 2026 in Washington, DC, November 14–17. Visit Inizio at booth #216 to discover how Real-World iNSIGHTS can uncover the perspectives that matter and help turn emerging evidence into actionable strategy.
Book a meeting with us onsite to learn more.
Jump to a slide with the slide dots.
In 2026, the non-small cell lung cancer (NSCLC) patient journey begins with biomarker testing and winds down a path cluttered with new treatments.
Read more
AI-powered and asynchronous solutions designed to meet the expectations of modern KOLs KOL expectations are changing,...
Read more
Elaine Ferguson explores how pharma leadership can support talent development, use AI to augment the workforce, and encourage continuous learning.
Read more
For years, omnichannel has focused on connecting channels and creating a more consistent HCP experience.
Read more
Omnichannel can provide more relevant, connected and scientific engagement. But sometimes, we in Medical Affairs tend...
Read more
